Inspyr (Formerly Known As GenSpera)
2511 N Loop 1604 W
Suite 204 (3rd Floor)
San Antonio
Texas
78258
United States
Tel: 210-479-8112
Fax: 210-479-8113
Website: http://www.inspyrtx.com/
About Inspyr (Formerly Known As GenSpera)
Inspyr Therapeutics is a biotechnology company focused on the development and commercialization of promising, new therapeutics. Our work is motivated by a commitment to innovation and helping patients. We combine our powerful insights and rigorous scientific methods to create new treatment options for patients.YEAR FOUNDED:
2003
LEADERSHIP:
CEO: Christopher Lowe
COO: Russell B. Richerson
CMO, SVP: Dr. Ronald L. Shazer
Interim Chairman: Peter E. Grebow
CLINICAL TRIAL:
Please click here for clinical trial information.
101 articles about Inspyr (Formerly Known As GenSpera)
-
Inspyr Therapeutics Further Strengthens Global Intellectual Property
2/18/2021
Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces additional expansion of its global intellectual property portfolio of adenosine receptor antagonists in China, Eurasia, and Israel. Management continues to execute on the expansion that further provides flexibility to pursue novel treatments
-
Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline
1/12/2021
Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces the sale of $500,000 of a senior convertible debenture ("Debenture") from an existing
-
Inspyr Therapeutics Reports 2020 Third Quarter Results and Business Update
11/24/2020
Implements New Corporate Strategy to Focus on Precision Therapeutics for the Treatment of Cancer Strengthens Pipeline by Acquiring a Proprietary Portfolio of Novel Adenosine Immuno-Modulator Compounds Increased Cash Runway by Securing $500,000 of Gross Proceeds From an Existing Institutional Investor in October 2020
-
Inspyr Therapeutics Announces Research Collaboration With the National Institutes of Health
10/23/2017
Dr. Elizabeth Kang initiates pre-clinical study for graft versus host disease.
-
Inspyr Announces Research Collaboration With NYU Winthrop Hospital
10/4/2017
-
Inspyr Announces Research Collaboration With University Of Virginia School Of Medicine
10/2/2017
-
Inspyr And Lewis And Clark Pharmaceuticals Complete Merger
9/13/2017
-
Inspyr Announces Private Placement Of Senior Convertible Debentures
9/12/2017
-
Inspyr And Lewis And Clark Pharmaceuticals To Merge
5/31/2017
-
Inspyr Appoints NIH Veterans To Lead New Translational Medicine Initiatives And Pipeline Expansion
3/6/2017
-
Inspyr Appoints Richard Buller, M.D., Ph.D. To Board Of Directors
10/13/2016
-
Inspyr Appoints Claire Thom, Pharm.D. To Board Of Directors
10/13/2016
-
Inspyr Announces The Initiation Of A Phase 2 Clinical Trial Of Mipsagargin For Newly Diagnosed Prostate Cancer Patients
8/17/2016
-
With a New Name and CEO, Inspyr Now Seeks a Partner for Cash to Fund Trial
8/10/2016
-
GenSpera Announces Name Change To Inspyr Therapeutics
8/2/2016
-
Biotech GenSpera's Future Uncertain as CEO and CFO Dionne Steps Down, Effective Immediately
3/23/2016
-
GenSpera Engages FLG Partners LLC And Partner Chris Lowe For Strategic Business Advisory Services
3/11/2016
-
GenSpera Issues Letter To Stockholders
1/6/2016
-
GenSpera Announces Private Placement Of $2.5 Million
12/28/2015
-
GenSpera To Present At ICV Manhattan Investor Conference
12/8/2015